3 results
The objectives of this trial are:1. To define the performance characteristics of FDHT PET in patients with metastasized castrate resistant prostate cancer(mCRPC).(a) To demonstrate the kinetics of displacement of the tracer off of the androgen…
Primary objective· • To investigate the safety and tolerability and establish either the dose of KU-0059436 which causes inhibition of PARP in combination with an active dose of carboplatin or the maximum tolerated dose (MTD) of KU-0059436 in…
Primary ObjectivesPhase 1bConfirm the recommended CyPep-1 dose 20 mg every two weeks (Q2W) when administered by intratumoral (IT) injection in combination with pembrolizumab Phase 2aAssess the anti-tumor activity of CyPep-1 administered by IT…